Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy
Authors:
Open Access
- 17 February 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (3) , 574-579
Abstract
OBJECTIVE: To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH DESIGN AND METHODS: Sixty type 1 diabetic adults with similar baseline characteristics, using either MDI (n = 30) or CSII (n = 30) therapy, were enrolled in this 6-month prospective study. Subjects were instructed to wear the DexCom SevenPLUS continuous glucose monitor at all times throughout the study. All subjects were initially blinded from the continuous glucose monitoring (CGM) glucose data. After 4 weeks of blinded CGM use, the CGM was unblinded, making glucose data available to the patient. The CGM remained in the unblinded state for the remainder of the study (20 weeks). Clinic visits occurred every 4 weeks, at which time A1C values were collected and CGM data were downloaded. RESULTS: Mean baseline (± SD) A1C was 7.61 (± 0.76) and 7.63 (± 0.68) for CSII and MDI, respectively (P > 0.05). Without any significant therapy change, A1C decrease at 12 weeks was similar in both groups (P = 0.03). When compared with the blinded phase, unblinded use of CGM was associated with similar but significant reductions in glycemic control and variability parameters. In addition, both therapy groups had similar changes in mean glucose and glucose variability indexes at 3 and 6 months (ITT analysis, P > 0.05). Predefined per protocol analysis (sensor use at least 6 days/week) showed greater improvement in time spent in target range glycemia, 3.9–10.0 mmol/L (70–180 mg/dL), in the CSII group. CONCLUSIONS: We conclude that CGM provides similar benefits in glucose control for patients using MDI or CSII therapy.Keywords
This publication has 22 references indexed in Scilit:
- Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose LevelsDiabetes Care, 2010
- Effectiveness of Continuous Glucose Monitoring in a Clinical Care EnvironmentDiabetes Care, 2009
- Evaluation of Urinary Biomarkers for Coronary Artery Disease, Diabetes, and Diabetic Kidney DiseaseDiabetes Technology & Therapeutics, 2009
- Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesNew England Journal of Medicine, 2008
- Continuous Home Monitoring of GlucoseDiabetes Care, 2007
- A method for assessing quality of control from glucose profilesDiabetic Medicine, 2007
- Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes Using Real-Time Continuous Glucose MonitoringDiabetes Care, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Use of the Continuous Glucose Monitoring System to Guide Therapy in Patients With Insulin-Treated Diabetes: A Randomized Controlled TrialMayo Clinic Proceedings, 2004
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993